{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:15:29Z","timestamp":1718889329581},"reference-count":25,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T00:00:00Z","timestamp":1498780800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openophthalmologyjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOOPHTJ"],"published-print":{"date-parts":[[2017,6,30]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To compare the safety and efficacy between switching to prostaglandin\/timolol fixed combination eye drops (PG\/timolol FCs) and adding brimonidine to PG analogue monotherapy.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Eyes of 53 patients with primary open-angle glaucoma or ocular hypertension who were receiving PG analogue monotherapy were included. Participants were randomly divided into two treatment groups: one was prescribed PG\/timolol FCs (switched group), and for the other, 0.1% brimonidine was added to the PG analogue (added group). Intraocular pressure (IOP), blood pressure, and pulse rate were measured after 1 and 3 months and compared to baseline values. Participants were also surveyed to determine if they had experienced systemic or topical adverse events at each study visit. IOP changes at 1 and 3 months were compared between groups.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Three months after changing medication, mean IOP was 14.6 \u00b1 2.4 mmHg in the switched group and 13.7 \u00b1 1.8 mmHg in the added group; both were significantly lower than the baseline values (switched group, 16.5 \u00b1 2.7 mmHg; added group, 15.8 \u00b1 2.3 mmHg; both P &lt; 0.001). Neither the mean nor the percentage reductions in IOP were significantly different between groups at 1 and 3 months. In the added group, diastolic blood pressure was lower than that at 1 and 3 months, systolic blood was lower than that at 3 months (P &lt; 0.01). The patients who had experienced systemic or topical adverse events were 53.8% in the added group and 40.7% in the the changed group, which was equivalent between groups (P =0.4142). Three patients (11.5%) in the added group, but none from the switched group, were excluded from analyses because of adverse events (not significant, P = 0.217).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Switching from a PG analogue to PG\/timolol FCs or to PG with brimonidine was equally safe (systemically and topically) and effective in reducing IOP. Thus, PG with brimonidine might be appropriate medication in patients who cannot use PG\/timolol FCs due to repiratory or circulatory disease.<\/jats:p>\n                <\/jats:sec>","DOI":"10.2174\/1874364101711010156","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T10:53:57Z","timestamp":1499424837000},"page":"156-163","update-policy":"http:\/\/dx.doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Switching from Prostaglandin Analog Therapy to Prostaglandin \/ Timolol Fixed Combination or Prostaglandin \/ Brimonidine Therapy"],"prefix":"10.2174","volume":"11","author":[{"given":"Kenji","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieko","family":"Masumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goji","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2147\/OPTH.S63760","volume":"8","author":"Schmier J.K.","year":"2014","unstructured":"Schmier JK, Hulme-Lowe CK, Covert DW. \n                    Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs. \n                    Clin Ophthalmol  \n                    2014; \n                    8\n                    : 1097-104.","journal-title":"Clin. Ophthalmol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","volume":"151","author":"Krupin T.","year":"2011","unstructured":"Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. \n                    Low-Pressure Glaucoma Study Group. \n                    A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. \n                    Am J Ophthalmol  \n                    2011; \n                    151\n                    (4)\n                    : 671-81.","journal-title":"Am. J. Ophthalmol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/bjo.2004.043232","volume":"88","author":"Hamacher T.","year":"2004","unstructured":"Hamacher T, Schinzel M, Sch\u00f6lzel-Klatt A, et al. \n                    Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%\/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. \n                    Br J Ophthalmol  \n                    2004; \n                    88\n                    (10)\n                    : 1295-8.","journal-title":"Br. J. Ophthalmol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/BF02849907","volume":"24","author":"Dunker S.","year":"2007","unstructured":"Dunker S, Schmucker A, Maier H. \n                    Latanoprost\/Timolol Fixed Combination Study Group. \n                    Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. \n                    Adv Ther  \n                    2007; \n                    24\n                    (2)\n                    : 376-86.","journal-title":"Adv. Ther."},{"key":"ref5","first-page":"157","volume":"40","author":"Polo V.","year":"2008","unstructured":"Polo V, Larrosa JM, Ferreras A, Borque E, Pablo LE, Honrubia FM. \n                    Effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% administered in the evening in glaucoma. \n                    Ann Ophthalmol (Skokie)  \n                    2008; \n                    40\n                    (3-4)\n                    : 157-62.","journal-title":"Ann. Ophthalmol. (Skokie)"},{"key":"ref6","first-page":"807","volume":"63","author":"Kitazawa Y","year":"2009","unstructured":"Kitazawa Y. \n                    KP2035 Study group. \u201cPhase 3 double-blind study of latanoprost\/timolol combination (KP2035) in patients with primary open-angle glaucoma or ocular hypertension [in Japanese]. \n                    Rinsho Ganka  \n                    2009; \n                    63\n                    : 807-15.","journal-title":"Rinsho Ganka"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2147\/OPTH.S30611","volume":"6","author":"Inoue K.","year":"2012","unstructured":"Inoue K, Okayama R, Higa R, Wakakura M, Tomita G. \n                    Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination. \n                    Clin Ophthalmol  \n                    2012; \n                    6\n                    : 607-12.","journal-title":"Clin. Ophthalmol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1358\/mf.2010.32.8.1501437","volume":"32","author":"Mandic Z.","year":"2010","unstructured":"Mandic Z, Novak-Lau\u0161 K, Bojic L, et al. \n                    Observational study of patients switched to the fixed travoprost 0.004%\/timolol 0.5% combination in Croatia. \n                    Methods Find Exp Clin Pharmacol  \n                    2010; \n                    32\n                    (8)\n                    : 593-8.","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"ref9","first-page":"459","volume":"4","author":"Pfeiffer N.","year":"2010","unstructured":"Pfeiffer N, Scherzer ML, Maier H, et al. \n                    Safety and efficacy of changing to the travoprost\/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy. \n                    Clin Ophthalmol  \n                    2010; \n                    4\n                    : 459-66.","journal-title":"Clin. Ophthalmol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2147\/OPTH.S30717","volume":"6","author":"Costa V.P.","year":"2012","unstructured":"Costa VP, Moreira H, Paolera MD, de Moraes Silva MR. \n                    Efficacy and safety of travoprost 0.004%\/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy. \n                    Clin Ophthalmol  \n                    2012; \n                    6\n                    : 699-706.","journal-title":"Clin. Ophthalmol."},{"key":"ref11","first-page":"1493","volume":"69","author":"Muraki T.","year":"2015","unstructured":"Muraki T, Inoue K, Ishida K, Tomita G. \n                    Long-term outcome of switching from travoprost to combination of travoprost and timolol [in Japanese]. \n                    Rinsho Ganka  \n                    2015; \n                    69\n                    : 1493-8.","journal-title":"Rinsho Ganka"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00061198-200106000-00014","volume":"10","author":"Lee D.A.","year":"2001","unstructured":"Lee DA, Gornbein JA. \n                    Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. \n                    J Glaucoma  \n                    2001; \n                    10\n                    (3)\n                    : 220-6.","journal-title":"J. Glaucoma"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.clinthera.2006.04.007","volume":"28","author":"Reis R.","year":"2006","unstructured":"Reis R, Queiroz CF, Santos LC, Avila MP, Magacho L. \n                    A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. \n                    Clin Ther  \n                    2006; \n                    28\n                    (4)\n                    : 552-9.","journal-title":"Clin. Ther."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ophtha.2004.11.032","volume":"112","author":"Konstas A.G.","year":"2005","unstructured":"Konstas AG, Karabatsas CH, Lallos N, et al. \n                    24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. \n                    Ophthalmology  \n                    2005; \n                    112\n                    (4)\n                    : 603-8.","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/BF02849898","volume":"24","author":"Mundorf T.","year":"2007","unstructured":"Mundorf T, Noecker RJ, Earl M. \n                    Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. \n                    Adv Ther  \n                    2007; \n                    24\n                    (2)\n                    : 302-9.","journal-title":"Adv. Ther."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ophtha.2007.03.012","volume":"114","author":"Feldman R.M.","year":"2007","unstructured":"Feldman RM, Tanna AP, Gross RL, et al. \n                    Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. \n                    Ophthalmology  \n                    2007; \n                    114\n                    (7)\n                    : 1248-54.","journal-title":"Ophthalmology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1185\/030079908X301848","volume":"24","author":"Day D.G.","year":"2008","unstructured":"Day DG, Hollander DA. \n                    Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. \n                    Curr Med Res Opin  \n                    2008; \n                    24\n                    (5)\n                    : 1435-42.","journal-title":"Curr. Med. Res. Opin."},{"key":"ref18","first-page":"679","volume":"29","author":"Araie M.","year":"2012","unstructured":"Araie M, Yamazaki Y, Sugiyama K, Kuwayama Y, Tanihara H. \n                    Long-term safety and efficacy of brimonidine ophthalmic solution in patient with primary open angle glaucoma or ocular hypertension [in Japanese]. \n                    Atarashii Ganka  \n                    2012; \n                    29\n                    : 679-86.","journal-title":"Atarashii Ganka."},{"key":"ref19","first-page":"899","volume":"31","author":"Yamamoto C.","year":"2014","unstructured":"Yamamoto C, Inoue K, Tomita G. \n                    Effect of brimonidine addition to prostaglandin analogs [in Japanese]. \n                    Atarashii Ganka  \n                    2014; \n                    31\n                    : 899-902.","journal-title":"Atarashii Ganka."},{"key":"ref20","first-page":"499","volume":"69","author":"Hayashi Y.","year":"2015","unstructured":"Hayashi Y, Hayashi F. \n                    Efficacy and safety of adding brimonidine to prostaglandin analogue for one year [in Japanese]. \n                    Rinsho Ganka  \n                    2015; \n                    69\n                    : 499-503.","journal-title":"Rinsho Ganka"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1089\/jop.2014.0174","volume":"31","author":"Aihara M.","year":"2015","unstructured":"Aihara M, Adachi M, Hamada N, et al. \n                    Effects of switching from timolol to brimonidine in prostaglandin analog and timolol combination therapy. \n                    J Ocul Pharmacol Ther  \n                    2015; \n                    31\n                    (8)\n                    : 482-6.","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref22","first-page":"955","volume":"116","author":"Araie M.","year":"2012","unstructured":"Araie M, Yamazaki Y, Sugiyama K, Kuwayama Y, Tanihara H. \n                    Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension-comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine\/prostaglandins therapy versus combination placebo\/prostaglandins therapy [in Japanese]. \n                    Nippon Ganka Gakkai Zasshi  \n                    2012; \n                    116\n                    (10)\n                    : 955-66.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0002-9394(01)00834-0","volume":"131","author":"Konstas A.G.","year":"2001","unstructured":"Konstas AG, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos NT. \n                    Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. \n                    Am J Ophthalmol  \n                    2001; \n                    131\n                    (6)\n                    : 729-33.","journal-title":"Am. J. Ophthalmol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/S0161-6420(98)91048-X","volume":"105","author":"LeBlanc R.P.","year":"1998","unstructured":"LeBlanc RP. \n                    Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. \n                    Ophthalmology  \n                    1998; \n                    105\n                    (10)\n                    : 1960-7.","journal-title":"Ophthalmology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0002-9394(98)00286-4","volume":"127","author":"Katz L.J.","year":"1999","unstructured":"Katz LJ. \n                    Brimonidine Study Group. \n                    Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. \n                    Am J Ophthalmol  \n                    1999; \n                    127\n                    (1)\n                    : 20-6.","journal-title":"Am. J. Ophthalmol."}],"container-title":["The Open Ophthalmology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openophthalmologyjournal.com\/contents\/volumes\/V11\/TOOPHTJ-11-156\/TOOPHTJ-11-156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openophthalmologyjournal.com\/contents\/volumes\/V11\/TOOPHTJ-11-156\/TOOPHTJ-11-156.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openophthalmologyjournal.com\/contents\/volumes\/V11\/TOOPHTJ-11-156\/TOOPHTJ-11-156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T06:30:04Z","timestamp":1555309804000},"score":1,"resource":{"primary":{"URL":"https:\/\/openophthalmologyjournal.com\/VOLUME\/11\/PAGE\/156\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,6,30]]}},"alternative-id":["TOOPHTJ-11-156"],"URL":"https:\/\/doi.org\/10.2174\/1874364101711010156","relation":{},"ISSN":["1874-3641"],"issn-type":[{"value":"1874-3641","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-01-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}